‼️Change is coming. Same trusted voice. A fresh new look. Check back on Monday. 👀 #PharmaIndustry #BrandEvolution #PharmTech

Nitrosamine analysis is evolving. Explore how LC-MS/MS and HRMS are helping analytical teams strengthen impurity detection and characterization for APIs and peptides. #MassSpectrometry hubs.li/Q04xnsV90

CPHI Americas 2026 is bringing together the leaders, innovators, and decision-makers who are shaping what’s next: from drug development to commercialization, supply chain resilience to manufacturing transformation. Learn more about the show here: hubs.li/Q04dbXhf0

High-concentration biologics are testing the limits of subcutaneous delivery. Formulation, device, and fill-finish experts break down where viscosity and stability constraints actually bite, and what it takes to get patients dosing at home. Register now: hubs.li/Q04xpd0V0

Inluriyo + Verzenio doubled PFS in ESR1-mutated breast cancer, 11.1 months vs. 5.5 in EMBER-3. It's two separately made oral solid dose products, not one pill. 🔗 See the manufacturing angle: hubs.li/Q04xZwQR0 #FDA #Oncology #PharmTech

Powders, granules, pellets or minitablets: your choice for a stick pack shapes taste masking, bioavailability and drug load. This webcast covers formulation strategy and how an integrated approach speeds development. Register now: hubs.li/Q04xTtWs0

There's usually a hard threshold in high-concentration biologics where viscosity makes everything downstream harder. The decision that trips it often happens in a different discipline entirely. Join us to learn why. Register now: hubs.li/Q04xS5sS0

AI can turn medical device risk management into a continuous signal instead of an annual review. Under EU MDR, that shift is becoming less optional and more expected. 🔗 See how the two-layer approach works: hubs.li/Q04xBnsP0 #AI #MedDevice #PharmTech

Sanofi is handing 20 mature medicines & 3 manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027, freeing up capital for R&D-led growth. Read more here👉hubs.li/Q04xtZ3c0 #Pharma #MA

Stick packs are gaining ground for precision dosing and convenience-driven therapies. Learn how to get the formulation, material selection and filling strategy right, and why an integrated single-campus model can speed up development. Register now: hubs.li/Q04xnnC10

"Work smarter, don't skip steps." Alfred Rumondor (AbbVie) & Swita Singh (BMS) preview their AAPS PharmSci 360 panel on the shift to formal, risk-based CMC flexibility & why cell & gene therapy no longer needs 3 PPQ batches. Watch the preview ➡️ hubs.li/Q04xbdyF0 #CMC

New modalities don't come with a playbook. AbbVie's Alfred Rumondor, PhD, and BMS's Swita Singh, PhD, preview their AAPS PharmSci 360 panel on building CMC strategy and where AI fits in. 🔗 Watch the preview: hubs.li/Q04x1F__0 #AAPSPharmSci360 #CMCChallenges

Why does eCOA planning need a six-month runway? Christy Owings of Thermo Fisher on how early supply chain partnership and site visits head off costly clinical trial delays. 🔗 Watch how: hubs.li/Q04w-krM0 #eCOA #PharmTech

AI isn't replacing clinical supply chain relationships. It's freeing them up. Christy Owings of Thermo Fisher on automating shipments and spotting shifts like China's pivot to ex-China approvals in Latin America. 🔗 Watch the breakdown: hubs.li/Q04wZKv20 #AI #PharmTech

CPHI Milan just got a glow-up. Four new zones landing Oct 6-8: AI & Tech, Cold Chain & Logistics, Contamination Control & Labeling. Tara Dougal breaks down what's new here👉 hubs.li/Q04wLZTM0 #CPHIMilan2026

Christy Owings, VP & GM Americas at Thermo Fisher, says vetted local partners & a solid importer of record strategy are what keep clinical trial supply chains reliable. Just a piece of the full conversation, but for more click👇 hubs.li/Q04wZH9W0 #ClinicalTrials #Pharma

The FDA just approved zilganersen, Ionis Pharmaceuticals' RNA therapy & the first disease-modifying treatment for Alexander disease. Developers are watching its 54-patient trial as a possible blueprint for ultra-rare CNS disease. Read more➡️ hubs.li/Q04wWZ730 #PharmTech

Clinical trial supply chains are getting more complex, and Latin America is where sponsors most underestimate the risk. Christy Owings, VP & GM Americas at Thermo Fisher, explains why early planning matters. Catch the rest of it here ➡️ hubs.li/Q04wDQdG0 #PharmTech

Novartis just paused 8 CAR T-cell trials after 3 patient deaths. The safety signal is specific to autoimmune and neurological patients, not oncology. Bristol Myers Squibb paused a rival program too. 🔗 See what changes for cell therapy: hubs.li/Q04wv67t0 #CART #PharmTech

40+ years proven, now purpose-built for pharma/biotech: RFID technology for cleanroom & facility-wide asset and personnel tracking. Learn how automated data capture improves compliance, quality, and operational efficiency. Register now: hubs.li/Q04rtGf30

Novartis is paying up to $3.2B for Alteogen's ALT-B4, the fourth subcutaneous conversion deal this year. For formulators: smaller volumes, higher concentrations & autoinjector-ready fill-finish. 🔗 See what changes on the line: hubs.li/Q04wkk9J0 #Formulation #PharmTech